Form S-1 Theriva Biologics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- McKesson reports cybersecurity incident affecting its information systems
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Theriva Biologics (TOVX) Files for 2.17M Share and Warrant Offering
September 10, 2024 5:07 PM EDTTheriva Biologics (NYSE: TOVX) has filed the following:
We are offering on a best efforts basis up to 2,173,913 shares of our common stock, par value $0.001 (the Common Stock), together with warrants to purchase up to 2,173,913 shares of our Common Stock. Each share of Common Stock, or a pre-funded warrant in lieu thereof, is being sold together with a common warrant to purchase one share of Common Stock (the Common Warrant). The shares of Common Stock and Common Warrants are immediately separable and will be issued separately in this offering,... More
